Breaking News Instant updates and real-time market news.

IRTC

iRhythm

$80.19

3.69 (4.82%)

16:13
10/30/18
10/30
16:13
10/30/18
16:13

iRhythm reports Q3 EPS (43c), consensus (45c)

Reports Q3 revenue $38.1M, consensus $35.88M.

  • 30

    Oct

IRTC iRhythm
$80.19

3.69 (4.82%)

09/06/18
CHDN
09/06/18
INITIATION
Target $117
CHDN
Buy
iRhythm initiated with a Buy at Chardan
Chardan analyst Steven Wardell started iRhythm Technologies with a Buy rating and $117 price target. The analyst believes good execution by management can drive 25% upside in the shares over the next 12 months. iRhythm has won strong acceptance from payers and growing adoption from providers while growing share, Wardell tells investors in a research note.
09/06/18
09/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Rite Aid (RAD) reinstated with a Sell at Goldman Sachs. 2. Parker-Hannifin (PH) initiated with an Overweight at Barclays. 3. iRhythm (IRTC) initiated with a Buy at Chardan. 4. Sarepta (SRPT) initiated with an Outperform at Credit Suisse. 5. Xperi (XPER) initiated with a Buy at National Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/18
ADAM
09/13/18
NO CHANGE
Target $100
ADAM
Buy
iRhythm weakness on Apple Watch an aggressive buying opportunity, says Canaccord
Canaccord analyst Jason Mills said he would be an aggressive buyer of iRhythm (IRTC) shares on weakness following the announcement of Apple's (AAPL)_next generation Watch Series 4. The analyst believes Apple's new watch will be a potential market expander of Zio, the iRhythm platform that is changing the paradigm in ambulatory ECG monitoring. He believes it could add another 3M tests to the TAM longer term. Mills reiterated his Buy rating and raised his price target to $100 from $93 on iRhythm shares.
09/13/18
JPMS
09/13/18
NO CHANGE
JPMS
Overweight
iRhythm selloff on Apple Watch a buying opportunity, says JPMorgan
JPMorgan analyst Robbie Marcus recommends investors use yesterday's weakness in shares of iRhythm Technologies (IRTC) as a buying opportunity. The stock sold off sharply after Apple (AAPL) announced that its new Watch Series 4 had received FDA approval for a built-in electrocardiogram scanner, Marcus tells investors in a research note. While the headline looks like a "notable headwind" for iRhythm, a closer look at the new device shows that this new feature poses almost no competitive threat to the company's Zio XT or AT offerings, Marcus contends. He does not see Apple turning the Watch into a regulated medical device approved for clinical diagnosis. The Apple Watch is approved for over-the-counter use and is not a continuous monitor, the analyst points out. Marcus believes Apple attaining an approval with a similar label to iRhythm's Zio "would significantly slow the rate of innovation and put the consumer device at the whim of the FDA." Instead, he expects that greater consumer preliminary screening for heart arrhythmias will only expand the number of patients seeking medical diagnosis, which, he feels, would benefit iRhythm. The analyst keeps an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

MIDD

Middleby

$126.19

2.13 (1.72%)

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Hot Stocks
Middleby announces retirement of CEO Selim Bassoul »

The Middleby Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEP

PepsiCo

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Recommendations
PepsiCo analyst commentary  »

PepsiCo price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 18

    May

PATK

Patrick Industries

$47.06

2.01 (4.46%)

07:36
02/19/19
02/19
07:36
02/19/19
07:36
Recommendations
Patrick Industries analyst commentary  »

Patrick Industries price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SB

Safe Bulkers

$1.60

-0.01 (-0.62%)

07:35
02/19/19
02/19
07:35
02/19/19
07:35
Earnings
Safe Bulkers reports Q4 adj. EPS 7c, consensus 8c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NXRT

NexPoint Residential

$38.40

0.13 (0.34%)

07:35
02/19/19
02/19
07:35
02/19/19
07:35
Earnings
NexPoint Residential sees FY19 AFFO $2.16, consensus $2.24 »

Sees FY19 Same Store NOI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

DE

Deere

$158.99

-3.45 (-2.12%)

07:35
02/19/19
02/19
07:35
02/19/19
07:35
Recommendations
Deere analyst commentary  »

Too early to write off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 27

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

07:34
02/19/19
02/19
07:34
02/19/19
07:34
Hot Stocks
Biohaven Pharmaceutical's verdiperstat receives FDA orphan drug designation »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$47.54

1.49 (3.24%)

07:34
02/19/19
02/19
07:34
02/19/19
07:34
Downgrade
Canopy Growth rating change  »

Canopy Growth downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NXRT

NexPoint Residential

$38.40

0.13 (0.34%)

07:33
02/19/19
02/19
07:33
02/19/19
07:33
Earnings
NexPoint Residential reports Q4 AFFO 47c, consensus 51c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

PRIM

Primoris

$21.29

0.09 (0.42%)

07:33
02/19/19
02/19
07:33
02/19/19
07:33
Hot Stocks
Primoris announces solar award valued over $170M »

Primoris announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NBL

Noble Energy

$22.63

0.62 (2.82%)

07:33
02/19/19
02/19
07:33
02/19/19
07:33
Hot Stocks
Noble Energy sees Q1 sales volumes 321-336 MBoe/d »

The Company anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NPO

EnPro

$72.21

2.81 (4.05%)

07:32
02/19/19
02/19
07:32
02/19/19
07:32
Downgrade
EnPro rating change  »

EnPro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 13

    Mar

SAH

Sonic Automotive

$15.85

-0.03 (-0.19%)

07:31
02/19/19
02/19
07:31
02/19/19
07:31
Hot Stocks
Sonic Automotive raises quarterly dividend 67% to 10c per share »

Payable in cash for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

CSL

Carlisle

$121.02

0.505 (0.42%)

07:31
02/19/19
02/19
07:31
02/19/19
07:31
Recommendations
Carlisle analyst commentary  »

Carlisle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 08

    Mar

  • 13

    Mar

  • 14

    Mar

FCAU

Fiat Chrysler

$14.75

0.09 (0.61%)

07:30
02/19/19
02/19
07:30
02/19/19
07:30
Downgrade
Fiat Chrysler rating change  »

Fiat Chrysler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHH

Choice Hotels

$80.53

-1.47 (-1.79%)

07:29
02/19/19
02/19
07:29
02/19/19
07:29
Recommendations
Choice Hotels analyst commentary  »

Choice Hotels reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTX

Aptinyx

$5.64

-0.07 (-1.23%)

07:29
02/19/19
02/19
07:29
02/19/19
07:29
Hot Stocks
Aptinyx doses first patient in Phase 2 NYX-783 study »

Aptinyx announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLXP

PLx Pharma

$5.11

-0.11 (-2.11%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Conference/Events
PLx Pharma to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

NBRV

Nabriva Therapeutics

$2.08

0.045 (2.22%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Hot Stocks
Nabriva Therapeutics announces FDA acceptance of lefamulin NDAs »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

WORX

SCWorx

$5.74

-0.07 (-1.20%)

07:27
02/19/19
02/19
07:27
02/19/19
07:27
Hot Stocks
SCWorx announces new customer service agreement »

SCWorx has expanded its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNC

Arconic

$17.56

0.07 (0.40%)

, JPM

JPMorgan

$105.56

3.14 (3.07%)

07:25
02/19/19
02/19
07:25
02/19/19
07:25
Hot Stocks
Arconic announces $700M accelerated share repurchase agreement »

Arconic (ARNC) announced…

ARNC

Arconic

$17.56

0.07 (0.40%)

JPM

JPMorgan

$105.56

3.14 (3.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:24
02/19/19
02/19
07:24
02/19/19
07:24
Hot Stocks
Intercept intends to file for OCA regulatory approval in U.S., Europe in 2H19 »

"We are thrilled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

CNMD

Conmed

$71.94

0.73 (1.03%)

07:24
02/19/19
02/19
07:24
02/19/19
07:24
Upgrade
Conmed rating change  »

Conmed reinstated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 18

    May

ACB

Aurora Cannabis

$7.04

-0.05 (-0.71%)

, TLRY

Tilray

$76.46

-0.2 (-0.26%)

07:23
02/19/19
02/19
07:23
02/19/19
07:23
Recommendations
Aurora Cannabis, Tilray, CV Sciences, Cronos Group, General Cannabis, CannTrust Holdings, Aphria, MediPharm Labs, Canopy Growth, India Globalization Capital analyst commentary  »

Moody's price target…

ACB

Aurora Cannabis

$7.04

-0.05 (-0.71%)

TLRY

Tilray

$76.46

-0.2 (-0.26%)

CVSI

CV Sciences

$0.00

(0.00%)

CRON

Cronos Group

$21.28

0.46 (2.21%)

CANN

General Cannabis

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

APHA

Aphria

$9.58

0.49 (5.39%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

IGC

India Globalization Capital

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

ICPT

Intercept

$110.77

-0.42 (-0.38%)

07:22
02/19/19
02/19
07:22
02/19/19
07:22
Hot Stocks
Breaking Hot Stocks news story on Intercept »

Intercept jumps 36% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.